|
Ovarian Cancer - Drug Pipeline Analysis and Market Forecasts to 2016 Summary The industry analysis specialist, has released a new report, “Ovarian Cancer - Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global ovarian cancer market. The report identifies the key trends shaping and driving the global ovarian cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ovarian cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the global ovarian cancer market to be valued at $697 million in 2009. It is forecast to grow by 13.1% annually for the next seven years to reach $1,650 million by 2016. This growth is primarily attributed to high prescription rate of existing chemotherapy, strong pipeline and advancement of new targeted therapies. Analyzed that the global ovarian cancer market is moderately served with current product options and significant scope available to new entrants that would capture value from underserved segments. Designing curable products with high efficacy and safety profile is one of key challenges of this market and could provide significant market share for any company. Analyzed that the global ovarian cancer market is increasingly becoming more competitive. Balancing the pipeline with the current marketed products and expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in ovarian cancer market is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects. Scope The scope of the report includes: * Annualized global ovarian cancer market revenues data from 2001 to 2009, forecast forward 7 years to 2016. * Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. * Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes topoisomerase inhibitor, drugs targeting DNA, vaccines, drugs targeting growth factor and growth factor receptors, folate receptor binder, kinase inhibitor, drugs targeting cytokines and combinations therapy. * Analysis of the current and future market competition in the global ovarian cancer market. Key market players covered are F. Hoffmann-La Roche Ltd/Genentech, Inc., Menarini Group, Novartis AG, Cell Therapeutics Inc., Telik, Inc. and BioNumerik Pharmaceuticals Inc. * Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. * Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with ovarian cancer. For more information, please visit: http://www.aarkstore.com/reports/Ovarian-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40533.html Or email us at press@aarkstore.com or call +919272852585 Aarkstore Enterprise Tel : +912227453309 Mobile No: +919272852585 Email : contact@aarkstore.com Website : http://www.aarkstore.com Blog: http://blogs.aarkstore.com/ Follow us on twitter: http://twitter.com/aarkstoredotcom
Related Articles -
Ovarian Cancer, Drug, Pipeline, Analysis, Market, Forecasts, Market, Research, Report, Business, Industry, Information, Automotive, Banking, Finance, ,
|
